Asian Market To See Increase

< BACK TO RESEARCH starstarstarstarstar   Science - Research Press Release
3rd February 2009, 07:23pm - Views: 1218

Science Research Frost & Sullivan 1 image

Asian Market to See Increase

SINGAPORE, /PRNewswire-AsiaNet/ --

               Oral Therapy in Type 2 Diabetes Therapeutics Market

     Although currently Metformins and SFUs are most preferred medications, in the future, new products such as

DPP-4, GLP-1, DGAT are likely to be used by the physicians which thereby increasing the number of type 2

patients on oral antidiabetic drugs. The use of oral therapy is likely to increase while the use of insulin would

decline due to the earlier detection of the disease. Patients are more compliant to early control and the availability

of an increasing array of oral antidiabetics. The global prevalence of diabetics is also driving the development of

new therapies and is resulting in pharmaceuticals companies to increase efforts on novel agents and therapies

that treat diabetes. 

    Frost & Sullivan Research Analyst Sushma Rajan says, across most countries there is sufficient government

support provided to control this disease, thus, there are minimal market restraints. In South Korea however,

the government has lack of support on programs and public educations for diabetes as they tend to focus on

other major diseases such as cancer. 

    "If compared to Taiwan, the government has set up a program for diabetes medical treatment through patient

self help groups, pay-for-performance scheme and also adopted various channels for diabetes education," Rajan

further elaborates.

    It is crucial for both government and pharmaceutical companies to create awareness about the disease and

enhance treatment acceptance by providing education programs. Through the increase in awareness, better

diagnosis and government initiatives, the number of patients diagnosed and treated will increase. This will then

open up a larger pool of patients for treatment than at present.

    Across the three countries namely, Australia, South Korea and Taiwan, in order to increase the usage of drugs,

manufactures need to bring their drugs under the reimbursement scheme so that drugs become affordable and

available to a larger patient pool.

    Opportunities exist for insulin manufactures in all Australia, South Korea and Taiwan to work with the Ministry

of Health for diabetes awareness, to encourage early detection and prevention of diabetes and educate physician

through seminars/conferences. 

    About Frost & Sullivan

    Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in

class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the

CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation,

evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of

experience in partnering with Global 1000 companies, emerging businesses and the investment community from

31 offices on six continents. To join our Growth Partnership, please visit


    Emmie Kaur

    Corporate Communications - Healthcare, Asia Pacific

    DID: +603 6204 5913


    Jasminder Kaur

    Corporate Communications - Healthcare, Asia Pacific

    DID: +65 6890 0937


SOURCE:  Frost & Sullivan

To view this and other AsiaNet releases please visit

news articles logo NEWS ARTICLES
Contact News Articles |Remove this article